International Journal of Clinical Oncology

, Volume 23, Issue 2, pp 329–337 | Cite as

Carcinosarcoma of the ovary compared to ovarian high-grade serous carcinoma: impact of optimal cytoreduction and standard adjuvant treatment

  • Ibrahim YalcinEmail author
  • Mehmet Mutlu Meydanli
  • Ahmet Taner Turan
  • Salih Taskin
  • Mustafa Erkan Sari
  • Tayfun Gungor
  • Ozgur Akbayir
  • Ali Ayhan
Original Article



The purpose of this retrospective study was to compare the prognoses of women with ovarian carcinosarcoma (OCS) who had optimal cytoreductive surgery followed by platinum plus taxane combination chemotherapy to those of women with ovarian high-grade serous carcinoma (HGSC) treated in the same manner.


A multicenter, retrospective department database review was performed to identify patients with OCS at eight gynecologic oncology centers in Turkey. A total of 54 women with OCS who had undergone optimal cytoreductive surgery followed by platinum plus taxane combination chemotherapy between 1999 and 2017 were included in this case–control study. Each case was matched to two women with ovarian HGSC who had undergone optimal cytoreductive surgery followed by platinum plus taxane combination chemotherapy. The Kaplan–Meier method was used to generate survival data. Factors predictive of outcome were analysed using Cox proportional hazards models.


Median disease-free survival (DFS) was 29 months [95% confidence interval (CI) 0–59, standard error (SE) 15.35] versus 27 months (95% CI 22.6–31.3, SE 2.22; p = 0.765) and median overall survival (OS) was 62 versus 82 months (p = 0.53) for cases and controls, respectively. For the entire cohort, the presence of ascites [hazard ratio (HR) 2.32; 95% CI 1.02–5.25, p = 0.04] and platinum resistance [HR 5.05; 95% CI 2.32–11, p < 0.001] were found to be independent risk factors for decreased OS.


DFS and OS rates of patients with OCS and HGSC seem to be similar whenever optimal cytoreduction is achieved and followed by platinum plus taxane combination chemotherapy.


High-grade serous ovarian cancer Optimal cytoreductive surgery Ovarian carcinosarcoma Platinum Taxane 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Seidman JD, Kurman RJ (2003) Pathology of ovarian carcinoma. Hematol Oncol Clin N Am 17(4):909–925CrossRefGoogle Scholar
  2. 2.
    Kounelis S, Jones MW, Papadaki H et al (1998) Carcinosarcomas (malignant mixed mullerian tumors) of the female genital tract: comparative molecular analysis of epithelial and mesenchymal components. Hum Pathol 29(1):82–87CrossRefPubMedGoogle Scholar
  3. 3.
    Krishnamurti U, Sasatomi E, Swalsky PA et al (2005) Microdissection-based mutational genotyping of serous borderline tumors of the ovary. Int J Gynecol Pathol 24(1):56–61PubMedGoogle Scholar
  4. 4.
    Shylasree TS, Bryant A, Athavale R (2013) Chemotherapy and/or radiotherapy in combination with surgery for ovarian carcinosarcoma. Cochrane Database Syst Rev 28(2):CD006246Google Scholar
  5. 5.
    Kobel M, Kalloger SE, Huntsman DG, Brown Ovarian Cancer Outcomes Unit of the British Columbia Cancer Agency VBC et al (2010) Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol 29(3):203–211CrossRefPubMedGoogle Scholar
  6. 6.
    Barakat RR, Berchuck A, Markman M et al (2013) Principles and practice of gynecologic oncology. 6th edn. Lippincott Williams & Wilkins, PhiladelphiaGoogle Scholar
  7. 7.
    Barnholtz-Sloan JS, Morris R, Malone JM et al (2004) Survival of women diagnosed with malignant, mixed mullerian tumors of the ovary (OMMMT). Gynecol Oncol 93(2):506–512CrossRefPubMedGoogle Scholar
  8. 8.
    Rauh-Hain JA, Growdon WB, Rodriguez N et al (2011) Carcinosarcoma of the ovary: a case–control study. Gynecol Oncol 121(3):477–481CrossRefPubMedGoogle Scholar
  9. 9.
    George EM, Herzog TJ, Neugut AI et al (2013) Carcinosarcoma of the ovary: natural history, patterns of treatment, and outcome. Gynecol Oncol 131(1):42–45CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Rauh-Hain JA, Diver EJ, Clemmer JT et al (2013) Carcinosarcoma of the ovary compared to papillary serous ovarian carcinoma: a SEER analysis. Gynecol Oncol 131(1):46–51CrossRefPubMedGoogle Scholar
  11. 11.
    Odicino F, Pecorelli S, Zigliani L et al (2008) History of the FIGO cancer staging system. Int J Gynaecol Obstet 101(2):205–210CrossRefPubMedGoogle Scholar
  12. 12.
    Paulsson G, Andersson S, Sorbe B (2013) A population-based series of ovarian carcinosarcomas with long-term follow-up. Anticancer Res 33(3):1003–1008PubMedGoogle Scholar
  13. 13.
    Signorelli M, Chiappa V, Minig L et al (2009) Platinum, anthracycline, and alkylating agent-based chemotherapy for ovarian carcinosarcoma. Int J Gynecol Cancer 19(6):1142–1146CrossRefPubMedGoogle Scholar
  14. 14.
    Rauh-Hain JA, Gonzalez R, Bregar AJ et al (2016) Patterns of care, predictors and outcomes of chemotherapy for ovarian carcinosarcoma: a National Cancer Database analysis. Gynecol Oncol 142(1):38–43CrossRefPubMedGoogle Scholar
  15. 15.
    Bristow RE, Tomacruz RS, Armstrong DK et al (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20(5):1248–1259CrossRefPubMedGoogle Scholar
  16. 16.
    du Bois A, Reuss A, Pujade-Lauraine E et al (2009) Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer 115(6):1234–1244CrossRefPubMedGoogle Scholar
  17. 17.
    Winter WE 3rd, Maxwell GL, Tian C et al (2008) Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 26(1):83–89CrossRefPubMedGoogle Scholar
  18. 18.
    Leiser AL, Chi DS, Ishill NM et al (2007) Carcinosarcoma of the ovary treated with platinum and taxane: the memorial Sloan-Kettering Cancer Center experience. Gynecol Oncol 105(3):657–661CrossRefPubMedGoogle Scholar
  19. 19.
    Ariyoshi K, Kawauchi S, Kaku T et al (2000) Prognostic factors in ovarian carcinosarcoma: a clinicopathological and immunohistochemical analysis of 23 cases. Histopathology 37(5):427–436CrossRefPubMedGoogle Scholar
  20. 20.
    Rauh-Hain JA, Birrer M, Del Carmen MG (2016) Carcinosarcoma of the ovary, fallopian tube, and peritoneum: prognostic factors and treatment modalities. Gynecol Oncol 142(2):248–254CrossRefPubMedGoogle Scholar
  21. 21.
    Chun KC, Kim JJ, Kim DY et al (2011) Optimal debulking surgery followed by paclitaxel/platinum chemotherapy is very effective in treating ovarian carcinosarcomas: a single center experience. Gynecol Obstet Invest 72(3):208–214CrossRefPubMedGoogle Scholar
  22. 22.
    Jernigan AM, Fader AN, Nutter B et al (2013) Ovarian carcinosarcoma: effects of cytoreductive status and platinum-based chemotherapy on survival. Obstet Gynecol Int 2013:490–508Google Scholar
  23. 23.
    Doo DW, Erickson BK, Arend RC et al (2014) Radical surgical cytoreduction in the treatment of ovarian carcinosarcoma. Gynecol Oncol 133(2):234–237CrossRefPubMedGoogle Scholar
  24. 24.
    Reed N, Millan D, Verheijen R et al (2010) Non-epithelial ovarian cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):31–36CrossRefGoogle Scholar
  25. 25.
    Duska LR, Garrett A, Eltabbakh GH et al (2002) Paclitaxel and platinum chemotherapy for malignant mixed mullerian tumors of the ovary. Gynecol Oncol 85(3):459–463CrossRefPubMedGoogle Scholar
  26. 26.
    Brown E, Stewart M, Rye T et al (2004) Carcinosarcoma of the ovary: 19 years of prospective data from a single center. Cancer 100(10):2148–2153CrossRefPubMedGoogle Scholar
  27. 27.
    Cicin I, Saip P, Eralp Y et al (2008) Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum. Gynecol Oncol 108(1):136–140CrossRefPubMedGoogle Scholar
  28. 28.
    Tate Thigpen J, Blessing JA, DeGeest K et al (2004) Cisplatin as initial chemotherapy in ovarian carcinosarcomas: a Gynecologic Oncology Group study. Gynecol Oncol 93(2):336–339CrossRefPubMedGoogle Scholar
  29. 29.
    Gynecologic Oncology Group (2014) A randomized phase III trial of paclitaxel plus carboplatin versus ifosfamide plus paclitaxel in chemotherapy-naive patients with newly diagnosed stage I–IV persistent or recurrent carcinosarcoma (mixed mesodermal tumor) of the uterus or ovary. Accessed 17 June 2017

Copyright information

© Japan Society of Clinical Oncology 2017

Authors and Affiliations

  1. 1.Department of Gynecologic Oncology, Faculty of Medicine, Zekai Tahir Burak Women’s Health Research and Training HospitalUniversity of Health SciencesAnkaraTurkey
  2. 2.Department of Gynecologic Oncology, Faculty of Medicine, Etlik Zubeyde Hanim Women’s Health Research and Training HospitalUniversity of Health SciencesAnkaraTurkey
  3. 3.Department of Gynecologic Oncology, Faculty of MedicineAnkara UniversityAnkaraTurkey
  4. 4.Department of Gynecologic OncologyKanuni Sultan Suleyman Research and Training HospitalIstanbulTurkey
  5. 5.Department of Gynecologic Oncology, Faculty of MedicineBaskent UniversityAnkaraTurkey

Personalised recommendations